Loading...

NUVB NUVATION BIO INC Product Launches 8-K Filing

NVTN

NVB

NUVATION BIO INC

(NUVB)

2025 8-K

Annual Meeting Results

Financial Results Announced

Financial Results Announced

New License Agreement

Drug Development Update

Positive Study Results

Financial Results Released

Earnings Releases

Pre-Market Approval

Financial Statements

Supply Agreement

Financial Results

Supply Agreement

Loan Agreements

Financial Results

CFO Appointment

Annual Meeting Results

Financial Results Announcement

Financial Results Announcement

Acquisition Completed

Merger Agreement

Financial Results Announcement

Appointment of Director

Resignation of Director

Financial Results Announcement

Financial Results Announcement

Annual Meeting of Stockholders

Financial Results Announcement

Earnings Reports

Petition for Resolution of ...

External Links:

Nuvation Bio Inc. reported positive Phase 2 results for safusidenib in IDH1-mutant gliomas, with an objective response rate of 44.4% and 87.9% progression-free at 24 months. The event was announced on November 17, 2025, detailing findings from a study conducted on November 8, 2025.

AI Assistant

NUVATION BIO INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.